Caprion and Vertex in biomarker collaboration

The collaboration will use Caprion’s CellCarta proteomics platform to support clinical biomarker discovery. Caprion will identify potential pharmacodynamic biomarkers in samples from certain undisclosed clinical and preclinical studies conducted by Vertex.

Caprion’s proprietary proteomics platform profiles proteins and provides an unprecedented level of protein expression and identification in tissues and blood plasma.

Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies, as well as its own clinical programs.

“Caprion is looking forward to working with Vertex on this clinical biomarker discovery collaboration,” noted Dr Daniel Chelsky, chief scientific officer at Caprion. “We believe that Caprion’s capabilities in the discovery of protein biomarkers may significantly impact development efforts for one or more Vertex compounds.”